Viatris, Inc. (VTRS)

Over the past six months, Viatris's stock has increased by 18.4%, outperforming the Health Care Select Sector SPDR Fund. As of February 2, 2026, the share price was $13.68, a 23.91% increase from February 3, 2025. On November 7, 2025, Viatris shares surged by 13.5% following its Q3 earnings release, which surpassed Wall Street estimates. In December 2024, Viatris received an FDA warning letter and import alert following an inspection of its manufacturing facility in Indore, India, which is expected to negatively affect 2025 revenues and adjusted EBITDA. The company has implemented a remediation plan and anticipates requesting an FDA reinspection.

The provided search results do not contain specific information about the demand seasonality for Viatris, Inc. products and services. While the company's Q3 2025 report mentions that seasonality may affect product demand, it does not elaborate on specific seasonal patterns.

Viatris Inc. is a global healthcare and pharmaceutical company created in November 2020 through the merger of Mylan and Pfizer's Upjohn division, headquartered in Canonsburg, Pennsylvania. The company focuses on maximizing the life cycle of proven medicines, offering a diversified portfolio of off-patent drugs, including prescription brand drugs, generic drugs, complex generic drugs, biosimilars, OTC drugs, and APIs. Its portfolio includes approximately 1,400 approved therapeutic molecules and iconic brands such as Viagra, Xanax, and Lipitor, covering a broad range of therapeutic areas. Generics and biosimilars account for roughly 40% of total sales, while legacy products contribute the remaining 60%. Viatris is also focusing on future innovations in dermatology, ophthalmology, and gastroenterology.

Viatris has a significant global presence, supplying medicines to approximately 1 billion patients annually across more than 165 countries and territories. The company operates in four main segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

Viatris has maintained a positive brand reputation, being named to Forbes' list of World's Best Employers for the fifth consecutive year in 2025. It was also included on TIME's list of World's Most Sustainable Companies 2024 and Forbes' list of World's Top Companies for Women 2024. The FDA warning letter and import alert concerning its Indore, India manufacturing facility could potentially impact its reputation, but the company is implementing a comprehensive remediation plan.

Viatris Inc. has a diverse ownership structure, with institutional investors holding 83.13% of the company's common stock as of June 2025. Major institutional shareholders include Vanguard Group Inc., T. Rowe Price Group, Inc., and BlackRock, Inc. Insiders held approximately 0.52% of the company's shares as of June 2025.